Market Overview:
The global rheumatoid arthritis therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of rheumatoid arthritis, rising awareness about available treatment options, and technological advancements in the field of rheumatoid arthritis therapeutics. The global rheumatoid arthritis therapeutics market can be segmented on the basis of type into pharmaceuticals and biopharmaceuticals. Pharmaceuticals are further sub-segmented into small molecules and biologics. Biologics are further sub-segmented into monoclonal antibodies (mAbs), fusion proteins, cytokines, and TNF inhibitors. On the basis of application, the global rheumatoid arthritis therapeutics market can be segmented into prescription drugs and over-the-counter (OTC) drugs. Prescription drugs are further sub-segmented into disease modifying anti-rheumatic drugs (DMARDs), corticosteroids, analgesics/antiinflammatory agents (AIA), biological response modifiers (BRMs), tumor necrosis factor alpha inhibitors (TNFαIs), anakinra injections, abatacept injections; while OTC drugs are further sub-segmented into pain relief medications such as ibuprofen or naproxen sodium tablets/capsules or acetaminophen products).
Product Definition:
Rheumatoid arthritis therapeutics is the term used to describe the various treatments available for rheumatoid arthritis, a condition that causes inflammation and pain in the joints. The importance of rheumatoid arthritis therapeutics lies in its ability to relieve symptoms and improve quality of life for people with this condition.
Pharmaceuticals:
Pharmaceuticals is the most commonly used class of drugs in Rheumatoid Arthritis (RA) therapeutics market.
Biopharmaceuticals:
Biopharmaceuticals are the drugs derived from living organisms. They are used to treat diseases caused by viruses, bacteria, and other pathogens. Biopharmaceuticals can be further classified into small molecule drugs and monoclonal antibodies. Small molecules constitute a large percentage of biologics currently in development; however, there is an increasing trend towards the use of monoclonal antibodies as they have greater therapeutic value than small molecules per dose and have fewer side effects.
Application Insights:
The prescription segment held the largest share of 66.1% in 2017 owing to high usage rates of anti-rheumatoid arthritis drugs among patients with RA. The OTC segment is expected to grow at a significant rate over the forecast period due to increasing use of non-prescription medicines for rheumatoid arthritis pain, which are available without a doctor¢â‚¬â„¢s prescription.
In addition, many pharmaceutical companies are focusing on the development and manufacturing of OTC products for people with mild or moderate symptoms associated with RA who have difficulty accessing healthcare services due to travel distance or cost constraints. This trend is expected drive growth in the near future as it offers an economical alternative for people living with this condition while still providing effective relief from joint pain and other associated symptoms such as fatigue and sleep disorders.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers, along with an increase in the prevalence of rheumatoid arthritis, is one major factor responsible for its largest share. In addition, increasing awareness about available treatment options and high healthcare expenditure are also contributing to its largest market share.
Asia Pacific is expected to be the fastest-growing region during the forecast period owing to factors such as improving healthcare infrastructure and growing patient awareness levels about available treatment options for rheumatoid arthritis. Moreover, an increase in disposable income levels will also contribute towards regional growth over the forecast period due to which it can provide lucrative opportunities for investors during this time span.
Key Companies: Pfizer Inc.
Growth Factors:
- Increasing incidence of rheumatoid arthritis
- Growing awareness about available treatment options for RA
- Rising demand for novel and targeted therapies for RA
- increasing healthcare expenditure by governments and private players to support the growth of the RA therapeutics market
- Technological advancements in rheumatoid arthritis therapeutics
Scope Of The Report
Report Attributes
Report Details
Report Title
Rheumatoid Arthritis Therapeutics Market Research Report
By Type
Pharmaceuticals, Biopharmaceuticals
By Application
Prescription, Over-the-Counter (OTC)
By Companies
AbbVie, Boehringer Ingelheim, Novartis, Regeneron Pharmaceuticals, Pfizer, Bristol-Myers Squibb, F. Hoffmann-La Roche, UCB S.A., Johnson & Johnson Services, Amgen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
192
Number of Tables & Figures
135
Customization Available
Yes, the report can be customized as per your need.
Global Rheumatoid Arthritis Therapeutics Market Report Segments:
The global Rheumatoid Arthritis Therapeutics market is segmented on the basis of:
Types
Pharmaceuticals, Biopharmaceuticals
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Prescription, Over-the-Counter (OTC)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Boehringer Ingelheim
- Novartis
- Regeneron Pharmaceuticals
- Pfizer
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- UCB S.A.
- Johnson & Johnson Services
- Amgen
Highlights of The Rheumatoid Arthritis Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Pharmaceuticals
- Biopharmaceuticals
- By Application:
- Prescription
- Over-the-Counter (OTC)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Rheumatoid Arthritis Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes inflammation of the joints. RA affects more than 1 million Americans, and it can be very debilitating. There are many different treatments available for RA, but most people require long-term treatment with medications and/or surgery.
Some of the key players operating in the rheumatoid arthritis therapeutics market are AbbVie, Boehringer Ingelheim, Novartis, Regeneron Pharmaceuticals, Pfizer, Bristol-Myers Squibb, F. Hoffmann-La Roche, UCB S.A., Johnson & Johnson Services, Amgen.
The rheumatoid arthritis therapeutics market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Rheumatoid Arthritis Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Rheumatoid Arthritis Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Rheumatoid Arthritis Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Rheumatoid Arthritis Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Rheumatoid Arthritis Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Rheumatoid Arthritis Therapeutics Market Size and Y-o-Y Growth
4.5.2 Rheumatoid Arthritis Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Pharmaceuticals
5.2.2 Biopharmaceuticals
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Prescription
6.2.2 Over-the-Counter (OTC)
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Rheumatoid Arthritis Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Rheumatoid Arthritis Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Pharmaceuticals
9.6.2 Biopharmaceuticals
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Prescription
9.10.2 Over-the-Counter (OTC)
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Pharmaceuticals
10.6.2 Biopharmaceuticals
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Prescription
10.10.2 Over-the-Counter (OTC)
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Pharmaceuticals
11.6.2 Biopharmaceuticals
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Prescription
11.10.2 Over-the-Counter (OTC)
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Pharmaceuticals
12.6.2 Biopharmaceuticals
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Prescription
12.10.2 Over-the-Counter (OTC)
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Pharmaceuticals
13.6.2 Biopharmaceuticals
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Prescription
13.10.2 Over-the-Counter (OTC)
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Rheumatoid Arthritis Therapeutics Market: Competitive Dashboard
14.2 Global Rheumatoid Arthritis Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie
14.3.2 Boehringer Ingelheim
14.3.3 Novartis
14.3.4 Regeneron Pharmaceuticals
14.3.5 Pfizer
14.3.6 Bristol-Myers Squibb
14.3.7 F. Hoffmann-La Roche
14.3.8 UCB S.A.
14.3.9 Johnson & Johnson Services
14.3.10 Amgen
